Year All20242023202220212020201920182017201620152014 Jan 05, 2022 Soleno Therapeutics to Participate in the LifeSci Partners 11th Annual Corporate Access Event Nov 19, 2021 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nov 10, 2021 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results Sep 23, 2021 Soleno Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference Sep 16, 2021 Soleno Therapeutics to Participate in the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit Sep 08, 2021 Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of PWS following One Year Treatment with DCCR Jul 28, 2021 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results Jul 06, 2021 Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome Jun 02, 2021 Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1a May 21, 2021 Soleno Therapeutics to Host Webinar Highlighting DCCR for Treatment of Prader-Willi Syndrome at European Congress on Endocrinology 2021
Jan 05, 2022 Soleno Therapeutics to Participate in the LifeSci Partners 11th Annual Corporate Access Event
Nov 10, 2021 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
Sep 23, 2021 Soleno Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
Sep 16, 2021 Soleno Therapeutics to Participate in the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
Sep 08, 2021 Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of PWS following One Year Treatment with DCCR
Jul 28, 2021 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results
Jul 06, 2021 Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
Jun 02, 2021 Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1a
May 21, 2021 Soleno Therapeutics to Host Webinar Highlighting DCCR for Treatment of Prader-Willi Syndrome at European Congress on Endocrinology 2021